Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Urges Prefectural Govts to Prep for 4th COVID Shot over Next 2 Months
March 28, 2022
- MHLW to Work Out Physician Payment Disclosure Method with Drug Makers towards Amendment of Clinical Research Law
March 28, 2022
- MHLW Panel OKs 84 More Health Damage Claims for COVID-19 Vaccines
March 28, 2022
- Japan Govt OKs 1.3 Trillion Yen Reserve Fund Use for COVID Measures
March 28, 2022
- PMDA Reviewing Safety Risks for Dexamethasone, Teicoplanin
March 28, 2022
- MHLW Study Group Proposes Using Private Data to Monitor Vaccine Distribution and Shortages
March 28, 2022
- Japan Inks Supply Deal for Shionogi’s COVID Pill for 1 Million People
March 25, 2022
- Japan Panel Agrees to Prep for Fourth Shot, but Wants Cautious Approach; Free Booster OK’ed for Ages 12-17
March 25, 2022
- Precedex Gets 1st Designation as Drug for Specific Use
March 25, 2022
- MHLW Study Group Kicks Off Discussions on Use of Pseudonymously Processed Information
March 25, 2022
- Opposition Party Mulls Counter-Legislation against PMD Law Amendment Bill
March 24, 2022
- CEFP Calls for Planned Healthcare Investments over Years
March 24, 2022
- Tentative List of Priority Infectious Diseases Expected by End of March
March 24, 2022
- PMDA to Publish Examples of Shortfalls Found in GMP Inspections
March 24, 2022
- Enhertu Braced for Price Cuts as Chuikyo OKs CEA Results; Evrysdi Not Subject to Scheme
March 24, 2022
- Alexion’s Bleeding Antidote to Be Approved as Early as This Month
March 24, 2022
- Pfizer COVID Booster OK’ed for Ages 12-17, Comirnaty Label Revised
March 24, 2022
- Ensure Appropriate Care System for Post-COVID Vaccination Symptoms: MHLW Panels
March 23, 2022
- PMDA to Launch “GMP Roundtable” with Academia, Industry
March 23, 2022
- Kyowa Pharma to Face Biz Suspension Order over Manufacturing Flaws
March 23, 2022
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…